Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Curevac NV (Curevac) is a biopharmaceutical company that develops new transformative medicines based on messenger ribonucleic acid (mRNA). The developing therapies in clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. CureVac pipeline includes a uropathogenic E. coli (UPEC) Vaccine for the prevention of urinary tract infections. CureVac is also developing a vaccine for Influenza. The company utilizes an mRNA technology platform designed to optimize mRNA constructs for therapeutic applications. It operates in Germany, the Netherlands, Belgium, Switzerland and the US. CureVac is headquartered in Tubingen, Baden-Wurttemberg, Germany.
Headquarters
Germany
Address
Friedrich-Miescher-Str. 15, Tuebingen, Baden-Wurttemberg, 72076
Website
www.curevac.com
Telephone
49 7071 98830
No of Employees
825
Industry
Pharmaceuticals and Healthcare
Revenue (2024)
$579.0M
Curevac NV premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Prophylactic Vaccines: |
| Uropathogenic E. coli (UPEC) Vaccine: Urinary Tract Infections (UTIs). |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Ownership Changes | In December, the company was acquired by BioNTech, a biotechnology company. |
| 2025 | Contracts/Agreements | In August, the company along with GSK BioNTech SE signed a partnership with BioNTech to secure a non-exclusive license for mRNA-based COVID-19 and/or Influenza Products and Resolve Patent Litigation. |
| 2024 | Plans/Strategy | In July, the company announced its plans to sell its experimental vaccines to GSK for US$430 million. |
Competitor Comparison
| Key Parameters | Curevac NV | Merck & Co Inc | Pfizer Inc | AstraZeneca Plc | Sanofi |
|---|---|---|---|---|---|
| Headquarters | Germany | United States of America | United States of America | United Kingdom | France |
| City | Tuebingen | Rahway | New York City | Cambridge | Paris |
| State/Province | Baden-Wurttemberg | New Jersey | New York | Cambridgeshire | Ile-de-France |
| No. of Employees | 825 | 73,000 | 81,000 | 96,100 | 76,493 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Alexander Zehnder | Chief Executive Officer | Senior Management | 2023 | 55 |
| Axel Sven Malkomes | Chief Financial Officer | Senior Management | 2024 | - |
| Malte Greune, Ph.D. | Chief Operating Officer | Senior Management | 2021 | 60 |
| Myriam Mendila, M.D. | Chief Scientific Officer; Head - Research and Development | Senior Management | 2023 | 59 |
| Thaminda Ramanayake | Chief Business Officer | Senior Management | 2024 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer